<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-9721</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Imunoalergologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Imunoalergologia]]></abbrev-journal-title>
<issn>0871-9721</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Alergologia e Imunologia Clínica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-97212023000200123</article-id>
<article-id pub-id-type="doi">10.32932/rpia.2023.04.109</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Autoadministração de omalizumab na urticária crónica espontânea - Estudo observacional num centro UCARE]]></article-title>
<article-title xml:lang="en"><![CDATA[Self-administration of omalizumab in chronic spontaneous urticaria - Observational study in a UCARE center]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bernardino]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Célia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Maria Inês T.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Amélia Spínola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Susana L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Neto]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário Lisboa Norte Hospital de Santa Maria Serviço de Imunoalergologia]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>123</fpage>
<lpage>135</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212023000200123&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212023000200123&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-97212023000200123&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Fundamentos:  O omalizumab (OMA) está aprovado para a urticária crónica espontânea (UCE) refratária aos anti-histamínicos. A possibilidade de autoadministração (AA) de OMA evita deslocações ao hospital, particularmente relevante em tempo de pandemia.  Objetivos:  Avaliaram-se o controlo da UCE, segurança da AA de OMA, grau de satisfação e redução dos custos para os doentes sob OMA em AA por período igual ou superior a 12 semanas e após duas sessões de ensino em Hospital de Dia (HD), entre janeiro e junho de 2021.  Métodos:  Aplicou-se um questionário(30 perguntas) visando a caracterização clínica/demográfica, terapêutica, reações adversas (RA), vantagens/preocupações percecionadas e avaliação de UCE em T0 (última administração em HD) e T1 (12 semanas em AA), por score de atividade da urticária nos últimos sete dias (UAS7), teste de controlo da urticária (UCT) e índice de qualidade de vida em dermatologia (DLQI).  Resultados:  Incluíram-se 25 doentes com tempo médio de UCE de 7,4 ±3,9 anos e duração do tratamento com OMA de 3,2 ±1,9 anos. À data do questionário, 52% tinham 3 AA de OMA 300mg, com periodicidade variável entre 4/4 semanas (44%) e 8/8 semanas (12%); 40% sem anti-histamínico associado. Em 88% administrado pelo próprio; 64% relatou igual intensidade de dor na AA face à administração em HD. Não se registaram RA graves. No controlo da UCE não se verificaram diferenças estatisticamente significativas nos scores entre T0 e T1. Todos consideraram a AA vantajosa, valorizando sobretudo a diminuição do tempo/custos despendidos. 48% referiu algum receio na AA, sobretudo na manipulação do OMA. A maioria (76%) considerou o processo simples e prático, valorizando os ensinos prévios em HD; 52% considerou não haver aspetos a melhorar; das sugestões apontadas, 28% referiam-se à simplificação do processo de entrega do OMA.  Conclusões:  O OMA em AA apresentou impacto positivo na satisfação dos doentes com UCE, mantendo-se o controlo da UCE e segurança terapêutica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  Omalizumab (OMA) is approved for antihistamine resistant chronic spontaneous urticaria (CSU). The possibility of self-administration (SA), is particularly convenient in current pandemic scenario, avoiding commutements to the hospital.  Objectives:  CSU control, SA safety, satisfaction, and cost reduction for patients under OMA SA therapy, during a period &#8805; 12 weeks and after 2 training sessions in Outpatient Hospital Care (OHC) were evaluated between January and June 2021.  Methods: A questionnaire (30 questions) was applied for the characterization of clinical/demographic data, therapy, adverse reactions (AR) and advantages/concerns related to OMA SA. Clinical evaluation of CSU was performed in T0 (last administration in OHC) and T1 (at12 weeks on SA), by urticaria activity score in the last 7 days (UAS7), urticaria control test (UCT) and dermatology life quality index (DLQI).  Results:  Twenty-five patients with a mean CSU duration of 7.4 ±3.9 years and under OMA for 3.2 ±1.9 years were included. At the time of the questionnaire, 52% had already 3 SA of OMA 300mg, with variable periodicity between 4/4 week (44%) and 8/8 week (12%); 40% without antihistamine H1 (anti-H1) therapy associated. In 88% OMA was SA by patient himself. 64% perceived equal pain intensity with SA than in OHC administration. No serious AR were reported. Regarding the control of CSU, there were no statistically significant differences between scores in T0 and T1. SA was considered advantageous by all patients, being valued the reduction of time/costs. About 48% reported some concerns with SA, especially in OMA manipulation. The majority (76%) considered a simple and practical procedure, valuing initial training sessions in OHC. For 52% there was no need for further improvement, while the simplification of the OMA delivery process was proposed by 28% of patients.  Conclusions:  OMA SA had a positive impact on satisfaction in patients with CSU, keeping up the good control and therapeutic safety.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Urticária crónica espontânea]]></kwd>
<kwd lng="pt"><![CDATA[omalizumab]]></kwd>
<kwd lng="pt"><![CDATA[autoadministração]]></kwd>
<kwd lng="pt"><![CDATA[satisfação]]></kwd>
<kwd lng="pt"><![CDATA[controlo clínico]]></kwd>
<kwd lng="pt"><![CDATA[segurança]]></kwd>
<kwd lng="en"><![CDATA[Chronic spontaneous urticaria]]></kwd>
<kwd lng="en"><![CDATA[omalizumab]]></kwd>
<kwd lng="en"><![CDATA[self-administration]]></kwd>
<kwd lng="en"><![CDATA[satisfaction]]></kwd>
<kwd lng="en"><![CDATA[clinical control]]></kwd>
<kwd lng="en"><![CDATA[safety]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuberbier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul Latiff]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Abuzakouk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aquilina]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Asero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The international EAACI/GA²LEN/EuroGuiDerm/ APAAACI guideline for the definition, classification, diagnosis, and management of urticaria]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2022</year>
<volume>77</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>734-66</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and therapeutic approach of chronic spontaneous urticaria: Recommendations in Portugal]]></article-title>
<collab>GPEU - Grupo Português de Estudos de Urticária</collab>
<source><![CDATA[Acta Med Port]]></source>
<year>2016</year>
<volume>29</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>763-81</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abuzakouk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bérard]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Oude Elberink]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Giménez-Arnau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2017</year>
<volume>72</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2005-16</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fricke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2019</year>
<volume>75</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>423-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonçalo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Questionário recomendado pelo Grupo Português de Estudos de Urticária (GPEU) para avaliação de doentes com urticária crónica em consulta]]></article-title>
<collab>GPEU - Grupo Português de Estudos de Urticária</collab>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2022</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Valle]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Dortas Jr]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[França]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of chronic urticaria on the quality of life of patients followed up at a university hospital]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2016</year>
<volume>91</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>754-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rosmaninho]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Guilherme]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline characteristics from a world-wide antihistaminerefractory chronic urticaria patient evaluation study (AWARE) from Portugal]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2019</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-40</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vestergaard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Toubi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Triggiani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ballmer-Weber]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Marsland]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion]]></article-title>
<source><![CDATA[Eur J Dermatol]]></source>
<year>2017</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giménez-Arnau]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Salman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeted therapy for chron&#305;c spontaneous urt&#305;car&#305;a: Rat&#305;onale and recent progress]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1617-34</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>European Medicines Agency Internet</collab>
<source><![CDATA[Summary of product characteristics - Xolair]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolkhir]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Altrichter]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Munoz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hawro]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New treatments for chronic urticaria]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2020</year>
<volume>124</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2-12</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brás]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Limão]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Esteves Caldeira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Paulino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab na urticária crónica espontânea: Experiencia de vida real no ajuste doses/ intrevalos e na suspensão do tratamento]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2021</year>
<volume>29</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>51</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carneiro-Leão]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Coimbra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Plácido]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gestão e plano de contingência do Serviço de Imunoalergologia do Centro Hospitalar e Universitário de S. João no contexto da pandemia por COVID-19]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2020</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>161-71</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Todo-Bom]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychometric properties of the portuguese version of the chronic urticaria quality of life questionnaire (CU-Q2oL)]]></article-title>
<source><![CDATA[Health Qual Life Outcomes]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>190</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Arruda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Munaini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validação de questionários de avaliação da qualidade de vida em pacientes de psoríase]]></article-title>
<source><![CDATA[An bras Dermatol]]></source>
<year>2004</year>
<volume>79</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>521-35</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Rainha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lourenço]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[n]]></surname>
<given-names><![CDATA[Santos]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudo de preferência da administração extra-hospitalar de omalizumab (exhoma)]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2019</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>351-2</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Timmermann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mailänder]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Home self-administration of biologics - a german survey among omalizumab-treated patients with severe asthma and their treating physicians]]></article-title>
<source><![CDATA[Pneumologie]]></source>
<year>2020</year>
<volume>74</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>103&#8209;11</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bernardino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gregorio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoadministração de omalizumab na asma: A experiência de um hospital central]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2021</year>
<volume>29</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>40-1</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Denman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[El-Shanaway]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Carne]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Devlin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Savic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria]]></article-title>
<source><![CDATA[Eur J Hosp Pharm]]></source>
<year>2020</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>367-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
